Elimination Half-Life of Short Peptide Drugs in Humans Extrapolated From Animal Pharmacokinetic Pharmacokinetic Studies
- Authors: Litvin A.A.1, Shevchenko R.V.1, Kolyvanov G.B.1, Bochkov P.O.1, Smirnov V.V.2, Raskin S.Y.1, Gribakina O.G.1, Zherdev V.P.1, Kolik L.G.1, Gudasheva T.A.1, Ivashkina N.Y.3
-
Affiliations:
- V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences
- I. M. Sechenov First Moscow State Medical University (Sechenov University)
- Maluna-Pharm Joint Stock Company
- Issue: Vol 53, No 8 (2019)
- Pages: 685-688
- Section: Article
- URL: https://ogarev-online.ru/0091-150X/article/view/245946
- DOI: https://doi.org/10.1007/s11094-019-02063-3
- ID: 245946
Cite item
Abstract
Results from an interspecies scaling study of the elimination half-lives of the anxiolytic GB-115 and the antipsychotic dilept in rats, rabbits, and humans are presented. The elimination half-lives of the studied drugs are calculated in real (chronological) and corrected time (pharmacokinetic). Elimination half-lives in animals and volunteers are compared. Rabbits are found to be a better scaling model for GB-115 although a single preference for dilept was not found.
Keywords
About the authors
A. A. Litvin
V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences
Email: lgkolik@mail.ru
Russian Federation, Moscow, 125315
R. V. Shevchenko
V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences
Email: lgkolik@mail.ru
Russian Federation, Moscow, 125315
G. B. Kolyvanov
V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences
Email: lgkolik@mail.ru
Russian Federation, Moscow, 125315
P. O. Bochkov
V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences
Email: lgkolik@mail.ru
Russian Federation, Moscow, 125315
V. V. Smirnov
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: lgkolik@mail.ru
Russian Federation, Moscow, 119991
S. Yu. Raskin
V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences
Email: lgkolik@mail.ru
Russian Federation, Moscow, 125315
O. G. Gribakina
V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences
Email: lgkolik@mail.ru
Russian Federation, Moscow, 125315
V. P. Zherdev
V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences
Email: lgkolik@mail.ru
Russian Federation, Moscow, 125315
L. G. Kolik
V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences
Author for correspondence.
Email: lgkolik@mail.ru
Russian Federation, Moscow, 125315
T. A. Gudasheva
V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences
Email: lgkolik@mail.ru
Russian Federation, Moscow, 125315
N. Yu. Ivashkina
Maluna-Pharm Joint Stock Company
Email: lgkolik@mail.ru
Russian Federation, Moscow, 125315
Supplementary files
